Moxidectin and ivermectin inhibit SARS-CoV-2 replication in Vero E6 cells but not in human primary airway epithelium cells

Nilima Dinesh Kumar¹,²#, Bram Ter Ellen²#, Ellen M. Bouma²#, Berit Troost², Denise P. I. van de Pol², Heidi H. van der Ende-Metselaar², Djoke van Gosliga⁴, Leonie Apperloo³ Orestes A. Carpaj⁵, Maarten van den Berge⁵, Martijn C. Nawijn³, Ymkje Stienstra⁶, Izabela A Rodenhuis-Zybert²#, Jolanda M. Smit²**

¹. Department of Biomedical Sciences of Cells & Systems, University of Groningen, University Medical Center Groningen, The Netherlands
². Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
³. Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, GRIAC Research Institute, 9700 RB Groningen, The Netherlands
⁴. Department of Pediatrics, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen, GRIAC Research Institute, 9700 RB Groningen, The Netherlands.
⁵. Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, GRIAC Research Institute, 9700 RB Groningen, The Netherlands
⁶. Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, The Netherlands

#These authors contributed equally

*Correspondence to jolanda.smit@umcg.nl

Jolanda M. Smit
Department of Medical Microbiology and Infection Prevention
Hanzeplein 1
Postbus 30.001
9700 RB Groningen
The Netherlands
Abstract

Antiviral therapies are urgently needed to treat and limit the development of severe COVID-19 disease. Ivermectin, a broad-spectrum anti-parasitic agent, has been shown to have anti-SARS-CoV-2 activity in Vero cells at a concentration of 5 µM. These in vitro results triggered the investigation of ivermectin as a treatment option to alleviate COVID-19 disease. In April 2021, the World Health Organization stated, however, the following: “the current evidence on the use of ivermectin to treat COVID-19 patients is inconclusive”. It is speculated that the in vivo concentration of ivermectin is too low to exert a strong antiviral effect. Here, we performed a head-to-head comparison of the antiviral activity of ivermectin and a structurally related, but metabolically more stable, moxidectin in multiple in vitro models of SARS-CoV-2 infection, including physiologically relevant human respiratory epithelial cells. Both moxidectin and ivermectin exhibited antiviral activity in Vero E6 cells. Subsequent experiments revealed that the compounds predominantly act on a step after virus cell entry. Surprisingly, however, in human airway-derived cell models, moxidectin and ivermectin failed to inhibit SARS-CoV-2 infection, even at a concentration of 10 µM. These disappointing results calls for a word of caution in the interpretation of anti-SARS-CoV-2 activity of drugs solely based on Vero cells. Altogether, these findings suggest that, even by using a high-dose regimen of ivermectin or switching to another drug in the same class are unlikely to be useful for treatment against SARS-CoV-2 in humans.

Keywords: moxidectin; ivermectin; antiviral; SARS-CoV-2; ALI, in vitro
1. Introduction

Within less than 1.5 year, the pandemic SARS coronavirus 2 (SARS-CoV-2) has infected over 153 million individuals and resulted in over 3.2 million deaths worldwide (Sohrabi et al., 2020; WHO, 2021a; Zhou et al., 2020). The social and economic burden of this still ongoing pandemic is staggering and besides vaccine development, it is of utmost importance to develop therapeutic interventions to reduce disease symptoms. To date, multiple compounds have been shown to exert SARS-CoV-2 antiviral activity in vitro and several compounds have reached clinical trials (Chan et al., 2020; Zhang et al., 2020). Remdesivir and hydroxychloroquine were thought to be effective early in the pandemic but after a careful evaluation in an interim solidarity trial, the WHO released a conditional yet strong recommendation against the usage of these drugs as no impact on overall mortality was observed (Consortium et al., 2021). Corticosteroids is currently (April 29th, 2021) the only therapeutic agent strongly recommended by the WHO for the treatment of severe and critical COVID-19 patients (Siemieniuk et al., 2020). These guidelines, however, differ from National Institute of Health (NIH) guidelines which recommend anti-SARS-CoV-2 monoclonal antibodies for selective patients with mild to moderate disease and remdesivir, dexamethasone and tocilizumab either individually or in combination based on the disease severity (NIH, 2021).

Ivermectin, a macrocyclic lactone of the avermectin subfamily, is a broad-spectrum antiparasitic agent approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) for prophylactic and therapeutic usage in some animal species and for selective treatments in humans (EMA, 2009, 2017; Makhani et al., 2019; Prichard et al., 2012). In recent years, ivermectin has also been shown to have antiviral activity in vitro towards several viruses including Zika virus (ZIKV) and dengue virus (DENV) (Gotz et al., 2016; Lundberg et al., 2013; Tay et al., 2013; Varghese et al., 2016; Wagstaff et al., 2012). In addition, Caly and colleagues (Caly et al., 2020) showed that ivermectin effectively
inhibits SARS-CoV-2 infection in Vero/hSALM cells. The success of ivermectin as an antiviral agent in vitro has, however, been proven difficult to translate to in vivo settings. For example, ivermectin failed to protect against lethal ZIKV challenge in mice (Ketkar et al., 2019) and did not reduce DENV viremia in phase III clinical trials (Yamasmith et al., 2018). It is speculated that the in vivo concentration of ivermectin is too low to exert its antiviral effect (Bray et al., 2020; Momekov and Momekova, 2020). Notably, despite the known limitation in achieving high ivermectin concentrations in humans (Pena-Silva et al., 2020; Schmith et al., 2020) and the limited in vitro proof of anti-SARS-CoV-2 activity (Caly et al., 2020), 65 ivermectin clinical trials (April 29th, 2021) are registered as treatment intervention against COVID-19 (clinicaltrials.gov, 2021). Recently, upon review of the latest trail results, many regulatory authorities including WHO issued a recommendation stating “to not use ivermectin in patients with COVID-19 except in the context of a clinical trial” as the available evidence to support its usage is uncertain (Chaccour et al., 2021; Gonzalez et al., 2021; Lopez-Medina et al., 2021; WHO, 2021b).

Moxidectin, a macrocyclic lactone belonging to the milbemycin subfamily and structurally related to ivermectin, is a broad-spectrum anti-parasitic used in veterinary medicine. In addition, it has recently been approved for human use for the prevention of river blindness, a disease caused by the parasite *Onchocerca volvulus* (Cobb and Boeckh, 2009; Milton et al., 2020; Prichard and Geary, 2019). Importantly, moxidectin has been shown to have superior drug disposition properties to ivermectin such as a longer half-life and higher efficacy in animals and humans (Opoku et al., 2018; Prichard and Geary, 2019). To date, antiviral potential of moxidectin towards SARS-CoV-2 has not been evaluated and no clinical trials are registered for moxidectin as COVID-19 treatment.

In this study, we evaluated the antiviral activity of moxidectin in direct comparison with ivermectin towards SARS-CoV-2 infection in vitro. We utilized the commonly used African
green monkey kidney (Vero E6) cells to compare the effective antiviral concentrations and to evaluate the longevity and mechanistic properties of the compounds. To verify the results in a physiological more relevant model system we subsequently tested the antiviral activity of both drugs in the human lung epithelial cells (Calu-3) and in primary human bronchial epithelial cells (PBECs) grown under air-liquid interface (ALI) culture conditions (Leist et al., 2020).
2. Materials and Methods

2.1. Chemicals and reagents

Ivermectin (Sigma-Aldrich, MO, USA) and moxidectin (European pharmacopeia reference standard, Strasbourg, France) were dissolved in absolute ethanol (EtOH) (Sigma-Aldrich, MO, USA) to a final concentration of 5 mM and stored at -20 °C. The maximum final EtOH concentration corresponded to 0.2% in all experiments.

2.2. Virus stock and titration

SARS-CoV-2 strain /NL/2020 (European Virus archive global (EVAg), 010V-03903) was produced in Vero E6 cells. The cells were infected at a multiplicity of infection (MOI) of 1 and 48 hours post-infection (hpi) supernatants containing progeny virions were harvested, centrifuged, aliquoted and stored at -80 °C. The obtained virus was passaged twice prior to usage for experiments. The infectious virus titer was determined by a plaque assay on Vero E6 cells. Briefly, Vero E6 cells were infected for 2 h with 10-fold serial dilutions of samples following, which, cells were overlaid with 1:1 mixture of 2% agarose (Lonza, Basel, Switzerland) and 2X MEM medium. At 72 hpi, the plaques were fixed using 10% formaldehyde (Alfa Aesar, Kandel, Germany) and stained using crystal violet (Sigma-Aldrich, MO, USA). Infectious titers are stated as plaque forming units (PFU) per ml. One plaque in 10-fold dilution corresponds to 150 PFU/ml and was set as the threshold of detection for all experiments.

2.3. Cell culture

The African green monkey Vero E6 cell line (ATCC CRL-1586), kindly provided by Gorben Pijlman (Wageningen University, Wageningen, the Netherlands) was maintained in Dulbecco’s minimal essential medium (DMEM) (Gibco, Paiskey, UK), high glucose supplemented with 10% fetal bovine serum (FBS) (Lonza, Basel, Switzerland), penicillin (100 U/mL), and streptomycin (100 U/mL) (Gibco, Paiskey, UK). The human lung epithelial cell line Calu-3
(ATCC HTB-55) was maintained in DMEM F-12 (Lonza, Basel, Switzerland) supplemented with 10% FBS, 1% Glutamax (Thermo Fisher Scientific, Inc., Waltham, MA, USA), 1% non-essential amino acid (Thermo Fisher Scientific, Inc., Waltham, MA, USA), penicillin (100 U/mL), and streptomycin (100 U/mL). All cells were mycoplasma negative and maintained at 37 °C under 5% CO₂. Primary human bronchial epithelial cells (PBECs) were cultured from bronchial brushing obtained by fibreoptic bronchoscopy performed using a standardized protocol during conscious sedation (Heijink et al., 2007; Vieira Braga et al., 2019). The medical ethics committee of the University Medical Center Groningen approved the study (METC 2019/338), and all subjects gave their written informed consent. The donors were 3 male and 2 female non-smoking healthy control volunteers, with a normal lung function (FEV/FVC > 70%, FEV₁ > 90% predicted) and absence of bronchial hyperresponsiveness to methacholine (PC₂₀ methacholine > 8 mg/ml). PBECs were cultured and fully differentiated under ALI conditions in transwell inserts, as previously described (Heijink et al., 2010).

2.4. Cytotoxicity assays

2.4.1. MTS assay

MTS assay, to determine cytotoxicity, was performed using the CellTiter 96® AQueous One Solution Cell Proliferation Assay kit using manufacturer’s instructions from Promega (Madison, WI, USA). Vero E6 cells were seeded in 96-well plates at a density of 10,000 cells/well. Following day, cells were treated with increasing concentrations of moxidectin or ivermectin ranging from 0 to 80 µM for 8 h or with 10 µM of both compounds for 60 h along with an equivalent volume of EtOH. Thereafter, 20 µl of the MTS/PMS reagent was added to each well and the cells were further incubated at 37 °C for 2 h. Subsequently, 10% SDS solution was added to stop the reaction and the absorbance was measured at 490 nm using a microplate reader (BioTek, Winnooski, VT). Calu-3 cells were seeded in 96-well plate at a density of 40,000 cells/well. Cells were treated with 5 and 10 µM moxidectin, ivermectin or an equivalent
volume of EtOH for 8 h. Same steps were followed as described above for Vero E6 cells. Cytotoxicity was determined based on the following formula:

\[
\% \text{ cytotoxicity} = \frac{(\text{absorbance sample} - \text{absorbance blank})}{(\text{absorbance negative control} - \text{absorbance blank})} \times 100
\]

2.4.2. LDH cytotoxicity assay

LDH assay was performed using the CyQUANT™ LDH Cytotoxicity Assay Kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA). PBECs cultured under ALI conditions were treated with 10 µM moxidectin, ivermectin or an equivalent volume of EtOH at the basolateral side for 48 h at 37 °C. Thereafter, LDH release was determined at the apical side. Hereeto, 200 µL of OptiMEM (Gibco, Paiskey, UK) was added to the apical side 30 min prior to the harvest. The apical harvest was clarified by centrifuging at 2000 x g at 4 °C. Levels of LDH were determined according to manufacturer’s instructions in all experimental conditions. The absorbance was measured at 490 and 680 nm using a microplate reader (BioTek, Winnooski, VT). Absorbance at 680 nm was subtracted from the absorbance at 490 nm and cytotoxicity was calculated as described below:

\[
\% \text{ cytotoxicity} = \frac{(\text{Compound treated LDH activity} - \text{spontaneous LDH activity})}{(\text{maximum LDH activity} - \text{spontaneous LDH activity})} \times 100
\]

2.4.3. Live/dead staining and flow cytometry

PBECs cultured under ALI conditions were treated with 10 µM moxidectin, ivermectin or an equivalent volume of EtOH at the basolateral side for 48 h at 37 °C. Subsequently, cells were harvested by trypsinization and stained with fixable viability dye eFluor780 (Thermo Fisher Scientific) for 20 min at 4 °C. Next, cells were washed with FACS buffer (1X PBS, 2% FBS, 1% EDTA), centrifuged and fixed with 4% PFA for 10 min at 4 °C. After fixation, cells were washed, centrifuged and resuspended in FACS buffer. Flow cytometry analyses was performed
using the LSR-2 flow cytometer (BD Biosciences, San Jose, CA, USA) and data was further analyzed using Kaluza analysis software, version 2.1 (Beckman Coulter, Fullerton, CA, USA).

2.5. Antiviral assay in Vero E6 and Calu-3

Vero E6 cells were seeded at a density of 1.3 x10^5 cells/well in 12-well plates. Next day, the medium was replaced with 0.25 mL of DMEM (2% FBS) medium containing the virus inoculum (MOI 1) and in presence of increasing concentration of compounds or the equivalent volume of EtOH. Following 2 h adsorption at 37 °C, the virus inoculum was removed, after which the cells were washed twice and fresh DMEM media (10% FBS) containing the compounds or EtOH was added. At 8 hpi, cell supernatants were harvested and titrated using plaque assay. For the durability assay, Vero E6 cells were infected with SARS-CoV-2 at MOI 0.01 and treated with 10 µM of moxidectin, ivermectin or the equivalent volume of EtOH. Supernatants were collected at 16, 24, 40 and 60 hpi. A lower MOI was used to allow multiple rounds of infection. Samples were titrated using plaque assay. Calu-3 cells were seeded at a density of 2 x10^5 cells/well in 24-well plates. At 48 h post-seeding, infection was performed in 0.2 mL of DMEM (2% FBS) medium containing virus inoculum (MOI 1) and 5 or 10 µM of moxidectin, ivermectin or the corresponding volume of EtOH. Cell supernatants were harvested at 8 hpi and titrated using plaque assay.

2.6. Antiviral assay in primary bronchial epithelial cells

Following 3 weeks of ALI culture, human primary bronchial epithelial cells (PBECs) were washed twice with OptiMEM to remove excess mucus. At the time of infection, 10 µM moxidectin, ivermectin or the equivalent volume of EtOH was added at the basolateral side of the insert (12-well). The apical side was inoculated with SARS-CoV-2 at MOI 5. At 2 hpi, cells were washed twice with OptiMEM and left on air at 37 °C until collection. Thirty minutes prior to collection (12, 24 and 48 hpi), 150 µL of OptiMEM was added to the apical side of the ALI
cultures and virus was harvested by incubating for 30 min at 37 °C. Infectious virus titers were determined using plaque assay.

2.7. Virucidal assay

SARS-CoV-2 particles (2.5 x 10⁵ PFUs) were incubated in the presence or absence of 10 µM moxidectin, ivermectin or the equivalent volume of EtOH for 2 h at 37 °C in 300 µl of DMEM media (2% FBS). Infectious virus titers were determined using plaque assay.

2.8. Time-of-drug-addition assay

For the time-of-drug-addition experiments, Vero E6 cells were treated with 10 µM moxidectin, ivermectin or the corresponding volume of EtOH either pre, during, or post-inoculation conditions (Fig. 2B). For pre-treatment, cells were incubated with the compounds for 2 h prior to infection. At the time of infection, cells were washed three times and infected with SARS-CoV-2 at MOI 1 for 2 h. At 2 hpi, cells were washed three times with plain DMEM, and media was replaced with DMEM 10% FBS, and incubation was continued until collection. For the “during” condition, the compounds were present together with the virus inoculum, thus only during the 2 h infection time. For the post-inoculation conditions, the compounds were added to the cell culture medium at 2, 4, and 6 h post-inoculation. All supernatants were collected at 8 hpi, clarified by centrifugation and used to quantify the infectious particle titers using plaque assay.

2.9. Statistical analysis

The concentration at which moxidectin and ivermectin reduced virus particle production by 50 and 90% is referred to as EC50 and EC90, respectively. Dose-response curves were fitted by non-linear regression analysis employing a sigmoidal model. All data were analyzed in GraphPad Prism software (La Jolla, CA, USA). Data are presented as mean ± SEM. Student T test was used to evaluate statistical differences between treated samples and a p value ≤ 0.05.
was considered significant with * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001 and ns as non-significant.

3. Results

3.1 Moxidectin and ivermectin inhibit SARS-CoV-2 infection in Vero E6 cells

First, we assessed the antiviral activity of moxidectin towards SARS-CoV-2 in the African green monkey kidney epithelial Vero E6 cell line and compared that to the efficacy of ivermectin. Vero E6 is highly permissive to SARS-CoV-2 infection (Matsuyama et al., 2020) and thus commonly used in studies investigating virus-host interactions and potential antiviral drugs. Prior to assessing the antiviral efficacy, we determined the cellular cytotoxicity of moxidectin and ivermectin in Vero E6 cells. A clear dose-dependent cytotoxicity was observed (Fig. S1). The highest non-toxic dose was set at 10 µM for subsequent experiments. At this concentration, the cell viability was above 90% for both moxidectin (Fig. S1A) and ivermectin (Fig. S1B). Next, Vero E6 cells were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 1 in presence of 10 µM moxidectin and ivermectin or the equivalent volume of EtOH and virus progeny was determined at 8 hpi. This time point corresponds to 1 cycle of replication (Ogando et al., 2020). SARS-CoV-2 infection under non-treated (NT) conditions led to a production of 4.9 ± 0.8 x10^5 PFU/mL (Fig. 1A). A comparable titer was observed for the EtOH control (4.3 ± 0.7 x10^5 PFU/mL), indicating that the solvent does not influence infectious virus particle production. In line with previous results (Caly et al., 2020), ivermectin was found to exert significant antiviral activity towards SARS-CoV-2 in Vero E6 cells (Fig.1). In presence of 10 µM ivermectin, infectious virus particle production was reduced to 1.9 ± 0.8 x10^2 PFU/mL, which corresponds to a reduction of more than 99.9% when compared to the EtOH control (Fig. 1A). In presence of 10 µM of moxidectin, the infectious virus titer was reduced to
4.3 ± 2.0 x10^2 PFU/mL which also corresponds to a reduction of 99.9% when compared to the EtOH control (Fig. 1A). Next, we performed a dose-response analysis to determine the EC_{50} and EC_{90} values (i.e. a reduction of 50% and 90% in viral titer, respectively). To this end, Vero E6 cells were infected with SARS-CoV-2 in the presence of increasing concentrations of both moxidectin, ivermectin, and the corresponding amount of EtOH. Moxidectin and ivermectin showed a dose-dependent antiviral activity in Vero E6 (Fig. 1B), with an EC_{50} and EC_{90} of 4.5 µM and 7.2 µM for moxidectin and 1.9 µM and 5.8 µM for ivermectin, respectively (Fig. 1B). The observed EC_{50} for ivermectin is in line with the previously published value of ~ 2µM (Caly et al., 2020). Thus, both compounds exhibit potent antiviral effects towards SARS-CoV-2, ivermectin being slightly more potent than moxidectin in this experimental set-up.

Given the known increased stability of moxidectin over ivermectin we next evaluated the durability of the antiviral effect for both compounds. To this end, Vero E6 cells were infected with SARS-CoV-2 at MOI 0.01 in presence of 10 µM of moxidectin, ivermectin or corresponding amount of EtOH and the cell supernatants were harvested at 16, 24, 40 and 60 hpi. These time points roughly correspond to 2, 3, 5 and 7 SARS-CoV-2 replication cycles, respectively (Ogando et al., 2020). Importantly, the prolonged incubation of the cells with moxidectin and ivermectin did not influence cell viability as measured with the MTS assay (Fig. S1C). At 40 hpi, 3.5 ± 0.4 x10^7 PFU/mL were produced at non-treated infection conditions and at this time point virus particle production reached its plateau (Fig. 1C). Comparable titers were observed over time for the EtOH control (3.4 ± 0.2 x10^7 PFU/mL at 40 hpi), indicating that EtOH had no effect on virus progeny production. More than 100-fold reduction in virus particle production was observed at 16, 24 and 40 hpi following infection in presence of moxidectin or ivermectin (Fig. 1C). At 60 hpi, ivermectin, showed antiviral activity for 2 experiments, yet there was a considerable variation between the other 2 experiments and therefore no significant antiviral effect was seen. In contrast, a moderate but consistent antiviral
effect of moxidectin was seen at 60 hpi. At this time point the titer reduced from $9.9 \pm 2.9 \times 10^6$ PFU/mL (EtOH control) to $1.5 \pm 1.0 \times 10^6$ PFU/mL, which corresponds to a reduction of 84.8%. Taken together, a single 10 µM dose of both compounds controlled SARS-CoV-2 replication for at least 5 replication cycles. For moxidectin, a more consistent antiviral effect is observed lasting until 7 replication cycles.

![Graph](image)

**Fig. 1.** Antiviral activity of moxidectin and ivermectin towards SARS-CoV-2 in Vero E6 cells. Vero E6 cells were treated with 10 µM moxidectin or ivermectin in the presence of SARS-CoV-2 at MOI 1. At 2 h post-infection (hpi), cells were washed twice with plain DMEM medium and new cell culture medium containing the compound was added and incubation was continued for another 6 h. At 8 hpi, cell supernatants were harvested and number of produced infectious virus particles were determined by plaque assay. (B) Vero E6 cells were treated with increasing concentrations of moxidectin or ivermectin and infection was continued as described above (A). The EC50 and EC90 values were calculated using GraphPad Prism software. (C)
Antiviral effect of 10 µM moxidectin or ivermectin or the corresponding volume of EtOH at 16, 24, 40 and 60 hpi. The dotted lines indicate the detection limit of plaque assay. Each dot represents data from a single independent experiment. Data are represented as mean ± SEM of at least three independent experiments. Statistical analysis was carried out by comparing treated samples with the EtOH control using Student’s t-test ** p < 0.001, *** p < 0.01, * p < 0.05 and ns as non-significant.

3.2 Moxidectin and ivermectin interfere with SARS-CoV-2 replication

To delineate the mode-of-action of the drug, we first investigated whether moxidectin and ivermectin exhibit a direct virucidal effect. To this end, 10 µM of moxidectin, ivermectin or the corresponding amount of EtOH control was incubated with 2.5 x10^5 SARS-CoV-2 particles at 37 °C for 2 h and the infectious titer was determined by plaque assay. The highest concentration in the diluted sample corresponded to 1 µM compound and at this concentration no antiviral effect in Vero E6 cells was observed (Fig. 1B) and therefore the plaque assay can be used as readout. Importantly, no differences in viral titer were observed between the moxidectin or ivermectin-treated samples and the EtOH control (Fig. 2A), indicating that these compounds do not exhibit virucidal activity to SARS-CoV-2 particles. Next, we performed a time-of-drug-addition assay. Here, 10 µM of moxidectin or ivermectin was administered either prior to virus inoculation, during virus inoculation, or post-virus inoculation (Fig. 2B). Cells were infected with SARS-CoV-2 at an MOI of 1 and supernatants were collected at 8 hpi to determine progeny infectious virus particle production. Each treatment included a corresponding EtOH control. No effect on the viral titers were observed when the compounds were added prior to inoculation. For the ‘during’ condition, no significant effect was seen for moxidectin and a significant albeit limited effect was observed for ivermectin. A strong reduction in viral titer was seen when the compounds were added at 2 hpi (Fig. 2C). For moxidectin, the infectious virus titer was reduced to 1.5 ± 1.0 x10^3 PFU/mL corresponding to a reduction of 98.6% and for ivermectin, the titer was reduced to 1.5 ± 0.8 x10^2 (99.9% reduction) when compared to the
corresponding EtOH control. No significant effect was seen when moxidectin or ivermectin were added at 4 or 6 hpi when compared to EtOH control (Fig. S2). Collectively, these results indicate that both moxidectin and ivermectin directly interfere with the viral infectious replication cycle in cells. This shows that the compounds either act at the early stages of RNA replication/translation (within 2-4 h post-infection) or that the compounds interfere with late stages of virus assembly/secretion (i.e. needs to be present for more than 4 h to exert its antiviral effect).

Fig. 2. Moxidectin and ivermectin predominantly inhibit SARS-CoV-2 at post-infection conditions. (A) Virucidal effect of moxidectin and ivermectin on SARS-CoV-2. (B) Schematic summary of the time-of-drug-addition experiment. (C) Vero E6 cells were infected with SARS-CoV-2 at MOI 1 for 2 h following which the inoculum was removed. Cells were treated with moxidectin or ivermectin at a concentration of 10 µM or the corresponding volume of EtOH as depicted in (B). At 8 hpi, cell supernatants were harvested and the virus titer was determined via plaque assay. The dotted lines indicate the detection limit of plaque assay. Each dot represents data from a single independent experiment. Data are presented as mean ± SEM for three independent experiments. Statistical analysis was carried out by comparing treated samples with the EtOH control using Student’s t-test. *** p < 0.001, ** p < 0.01, and * p < 0.05 and ns as non-significant.
3.3 Moxidectin and ivermectin do not exhibit anti-SARS-CoV-2 activity in Calu-3 and primary human bronchial epithelial cells

We next sought to validate the antiviral potential of moxidectin and ivermectin in the human lung epithelial Calu-3 cells, cells which have previously been shown to support SARS-CoV-2 replication (Chu et al., 2020). Prior to infectivity assays, the cellular cytotoxicity of both compounds at 5 and 10 µM was determined using the MTS assay. At these concentrations, no cytotoxicity was observed (Fig. S3). Accordingly, we proceeded by infecting Calu-3 cells with SARS-CoV-2 at MOI 1 in the presence or absence of 5 µM and 10 µM of moxidectin or ivermectin. In the absence of the drugs (NT condition), infection led to a release of on average, 1.5 ± 2.3 x10^4 PFU/mL at 8 hpi (Fig. 3A). A comparable titer was observed for the EtOH control (1.7 ± 2.5 x10^4 PFU/mL). To our surprise, however, no significant reduction in viral titers was observed following infection in presence of moxidectin and ivermectin, indicating that at these experimental conditions, the compounds did not exhibit an antiviral effect in Calu-3 cells.

As the human respiratory tract represents the primary site of virus infection (Jonsdottir and Dijkman, 2016), we decided to further verify the antiviral activity of moxidectin and ivermectin in a human-based cell system. Hereto, we used PBECs cultured under ALI culture system. Cells grown under ALI conditions undergo cellular differentiation, thus mimicking crucial physiological properties similar to that found in vivo (Cao et al., 2020; Jia et al., 2005; Sims et al., 2008). Prior to performing the antiviral assays in this model system, we first assessed the cytotoxicity of 10 µM moxidectin and ivermectin at 48 h of treatment using live-death staining and a LDH release assay. Both assays showed a viability above 90% compared to EtOH control (Fig. S4). ALI-cultured PBECs were incubated with 10 µM of moxidectin or ivermectin at the basolateral side and infected with SARS-CoV-2 at MOI 5 at the apical side as indicated in the schematics (Fig. 3B). Supernatants were harvested from the apical side at 12, 24 and 48 hpi and titers were determined using plaque assay. Importantly, despite the strong antiviral effect in Vero E6 cells, no significant antiviral activity was seen in the apical washes of moxidectin or
ivermectin treated PBECs when compared to the EtOH control at all-time points tested (Fig. 3C). Next to moxidectin and ivermectin, we also tested antiviral activity of resveratrol in the same donors and observed a potent antiviral effect in this model system thereby confirming the validity of the experimental settings (Ellen et al., 2020).

Fig. 3. Moxidectin and ivermectin have no significant effect on SARS-CoV-2 infection in human-derived cell models. (A) Calu-3 cells were treated with 5 and 10 μM of moxidectin or ivermectin or the highest respective concentration of EtOH in presence of SARS-CoV-2 at MOI 1. At 8 hpi, cell supernatants were harvested and the number of produced infectious virus particles were determined by plaque assay. Each dot represents data from a single independent
experiment. **(B)** Schematic representation of the experimental design. (1) Scheme of experiments in primary (PBECs). The cells were cultured on permeable inserts under Air Liquid Interface (ALI) conditions for ~ 3 weeks. (2) Cells were inoculated with SARS-CoV-2 MOI 5 at the apical side of the insert and treated with 10 µM of moxidectin, ivermectin or the corresponding volume of EtOH at basolateral side until the collection time as shown in the schematics (3) Following virus inoculation, virus was removed by washing with media and the cells were left under ALI conditions until virus collection. (4) For final collection, cells were incubated with medium for 30 min and produced progeny virus was collected. After collection, cells were exposed to air again (3) until the next collection time point where steps 4 and 3 were repeated until the end of treatment. **(C)** The antiviral activity of moxidectin and ivermectin in PBECs. Dotted lines indicate the threshold of detection. Scheme adapted from STEMCELL Technologies (STEMCELL, 2021). Each dot represents data from a single independent experiment. Data is represented as mean ± SEM from five different donors. Student t-test was used to evaluate statistical differences and a p value ≤ 0.05 was considered significant with *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 and ns as non-significant.

4. Discussion

We confirm previously published antiviral activity of ivermectin (Caly et al., 2020) in Vero E6 cells and showed an antiviral effect of moxidectin against SARS-CoV-2 in these cells. Further in-depth mode-of-action experiments revealed that moxidectin and ivermectin actively interfere with virus replication. Unfortunately, despite the promising antiviral properties of moxidectin and ivermectin in Vero E6 cells, the drugs did not show any antiviral activity in human airway-derived cell models. Collectively, the data show that the potency of moxidectin and ivermectin are species or cell-type specific and provide an explanation for the discordant findings in literature where positive effects were found in Vero cells, but no clinically relevant patient outcomes could be demonstrated in human studies.

To demonstrate which steps of the SARS-CoV-2 replication cycle are affected by moxidectin or ivermectin in Vero E6 cells, we performed a time-of-drug-addition experiments. The strongest effect was seen when moxidectin or ivermectin are added after the onset of infection suggesting the compounds do not interfere with processes related to viral entry like virus-cell binding, internalization or membrane fusion. We hypothesize that the compounds either directly...
interfere with early stages of RNA translation/replication or indirectly at late stages of the virus replication cycle (due to prolonged incubation). Other studies revealed that ivermectin blocks replication of HIV-1 and DENV viruses (Tay et al., 2013; Wagstaff et al., 2012), by binding and inhibiting cellular importin (IMP) α/β- mediated transport of viral proteins to the nucleus (Wagstaff et al., 2011; Wagstaff et al., 2012). Ivermectin has also been shown to inhibit NS3 helicase activity thereby inhibiting flavivirus replication (Mastrangelo et al., 2012). Our findings hint towards a mechanism where both drugs restrict SARS-CoV-2 replication by modulating cellular factors or processes, which control replication in Vero E6 cells but are absent in human-derived Calu-3 and PBECs.

Currently (April 29th, 2021), 65 clinical trials are registered that evaluate the efficacy of ivermectin as a prophylactic or therapeutic drug and 21 of these are completed (clinicaltrials.gov, 2021). Many of these trials have serious limitations such as small sample size, lack of binding, lack of pre-registration for some trials and therefore carries a risk of bias (Ahmed et al., 2021; Chaccour et al., 2021; Chowdhury et al., 2020; Elgazzar et al., 2020; Hashim et al., 2020; Okumuş et al., 2021; Podder et al., 2020; Rajter et al., 2021; Soto-Becerra et al., 2020; WHO, 2021b). Apart from the problem of bias, only five trials (April 29, 2021), directly compared ivermectin with standard of care and reported clinically crucial outcomes such as mortality (Gonzalez et al., 2021; Lopez-Medina et al., 2021; Mohan et al., 2021; Niaee et al., 2020; Ravikirti. et al., 2021). The WHO recently stated: “the current evidence of effect of ivermectin on mortality, mechanical ventilation, hospital admission and duration of hospitalization remains uncertain” (WHO, 2021b). Yet, many clinical trials are still ongoing. The observed lack of antiviral activity of ivermectin in the biologically relevant PBECs model reported here together with the poor pharmacological properties of ivermectin (Momekov and Momekova, 2020; Pena-Silva et al., 2020; Schmith et al., 2020) do not forecast a success of the ongoing clinical trials for its usage in COVID-19 patients.
SARS-CoV-2 can also infect several economically important livestock such as cats, dogs, minks, lions and tigers (Lam et al., 2020; McAloose et al., 2020; Oreshkova et al., 2020; Patterson et al., 2020; Sharun et al., 2020; Shi et al., 2020). Inhibition of virus replication in these animals could thus offer an effective strategy to control virus dissemination. Both drugs inhibited SARS-CoV-2 infection in African green monkey-derived kidney epithelial (Vero E6) cells. Since both the compounds have already been FDA-approved for the use in animals (Gonzalez Canga et al., 2009; Nolan and Lok, 2012), our results in Vero E6, warrant follow-up studies in relevant animal cell systems to assess their potential as antivirals in economically important livestock.

In conclusion, we elucidated that while both moxidectin and ivermectin exhibit antiviral activity in Vero E6, they do not reduce SARS-CoV-2 replication in human airway-derived cell models. While immortalized cells lines such as Vero E6 may be useful in a primary screening of inhibitors, it is important to determine true relevance of the inhibitors in a biological relevant model. In humans, airway epithelium is the main target for SARS-CoV-2 (de Melo et al., 2020; Leist et al., 2020) and therefore PBECs grown under ALI conditions, but not Vero cells, mimic crucial physiological properties similar to that found in vivo (Cao et al., 2020; Jia et al., 2005; Sims et al., 2008). We therefore advocate more rigorous antiviral drug testing in relevant systems prior to evaluating their efficacy in clinical trials.

Acknowledgements

The authors thank dr. Y. Bhide for help in the design of experiments. Grant support was provided by University Medical Center of Groningen and Marie Skłodowska-Curie Cofund (713660). N.D.K, B.M.E, E.M.B, M.C.N, Y.S, I.A.R.Z. and J.M.S designed the experiments. N.D.K, B.M.E, E.M.B, B.T, D.P.I.P, H.H.E, D.G, L.A, executed the experiments. O.A.C and
M.B selected recruited donors and sampled donors. N.D.K, E.M.B, I.A.R.Z and J.M.S wrote the manuscript. All authors edited the manuscript.

References


EMA, 2017. Moxidectin-containing veterinary medicines used in cattle, sheep and horses


Momekov, G., Momekova, D., 2020. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnology & Biotechnological Equipment 34, 469-474.


